Selecta Biosciences (SELB) Tops Q2 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. ENPH
2. HOOD
3. NXPI
4. SPY
5. BA
6. STX
7. GOOGL
8. NOW
9. CSGP
10. LSTR

Go back to Selecta Biosciences (SELB) Tops Q2 EPS by 16c

Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 12, 2021 8:00 AM EDT

IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during the third quarter of 2021; Manufacturing issue has been resolved, with a new completed lot undergoing final release testingSEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021Selecta achieved $3 million milestone payment from Sarepta Therapeutics related to successfully meeting the criteria for a preclinical studyAs of June 30, 2021, Selecta had approximately $151.5 million in cash, cash equivalents, and marketable securities which is expected to... More